Lotiglipron

Lotiglipron is a non-peptide GLP-1 receptor agonist which was under development by Pfizer as a weight loss drug.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Lotiglipron is a non-peptide GLP-1 receptor agonist which was under development by Pfizer as a weight loss drug. However, it was withdrawn from development in June 2023, after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.

See also

Danuglipron Orforglipron

Text derived from https://en.wikipedia.org/w/index.php?oldid=1330084634 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001330084634 · captured 2025-12-29 · ledger · version history

Cite this page as: encyclopegia.org, “Lotiglipron”, snapshot enwiki-001330084634. https://encyclopegia.org/a/lotiglipron

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.